Welcome to our dedicated page for Rapport Therapeutics news (Ticker: RAPP), a resource for investors and traders seeking the latest updates and insights on Rapport Therapeutics stock.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company that regularly issues news about its precision neuroscience programs for neurological and psychiatric disorders. The company’s updates often center on RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator being evaluated in drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain.
News for RAPP commonly includes clinical trial milestones, such as Phase 2a results in focal onset seizures, post hoc analyses presented at scientific meetings, and plans for registrational Phase 3 programs. Rapport has reported statistically significant reductions in long episodes and clinical seizures in its Phase 2a FOS trial, along with additional analyses on early onset of action, consistency of response, and improvements in seizure severity measures.
Investors and clinicians following Rapport can also expect announcements about regulatory interactions with the U.S. Food and Drug Administration, including end-of-Phase 2 meetings, clinical hold updates, and investigational new drug (IND)-enabling activities. The company provides updates on its long-acting injectable formulation of RAP-219, its α6β4 nicotinic acetylcholine receptor program for chronic pain and migraine, and other discovery and preclinical efforts in hearing and vestibular disorders.
RAPP news flow further covers financial and corporate developments, such as public offerings of common stock under an effective shelf registration statement, quarterly financial results, and participation in healthcare and investor conferences. For readers tracking Rapport Therapeutics, this news stream offers insight into the progress of its RAP technology platform, the evolution of its epilepsy portfolio, and the status of its broader pipeline in neurology and psychiatry.
Rapport Therapeutics (NASDAQ: RAPP) reported Q1 2025 financial results and provided key business updates. The company's lead program RAP-219 is progressing with two significant Phase 2a trials: one for refractory focal epilepsy with topline results expected in Q3 2025, and another for bipolar mania starting in Q3 2025. The company reported favorable tolerability across four Phase 1 trials, with PET data showing selective targeting in epilepsy-associated brain regions.
Financial highlights include a Q1 2025 net loss of $24.1 million, with R&D expenses of $19.6 million and G&A expenses of $7.5 million. The company maintains a strong financial position with $285.4 million in cash and investments, expected to fund operations through 2026. Recent appointments include Dr. Jeffrey Sevigny as Chief Medical Officer, and the company plans to host its inaugural Investor and Analyst Day on June 2, 2025.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company focusing on small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in three major investor conferences in April and May 2025.
The company will participate in:
- Jones Trading Virtual CNS Symposium - fireside chat on April 29, 2025 (11:00-11:25am ET)
- Citizens JMP 2025 Life Sciences Conference in New York City - fireside chat on May 8, 2025 (1:30-1:55pm ET)
- Mizuho Neuro & Ophthalmology Summit 2025 in New York City - investor meetings on May 21, 2025
Live and archived webcasts of the Jones Trading and Citizens JMP fireside chats will be accessible through the Investors section of Rapport's website.
Rapport Therapeutics (Nasdaq: RAPP) has announced two encore poster presentations at the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego from April 5-9, 2025. The presentations will focus on RAP-219, their clinical-stage AMPA receptor negative allosteric modulator in Phase 2 development for refractory focal epilepsy.
The first poster (#002) will present ROC analysis data showing that a 30% reduction in long episode frequency predicts a clinically meaningful reduction (≥50%) in clinical seizures. The second poster (#003) will demonstrate RAP-219's potent antiseizure effects in preclinical models, with maximal protection achieved at 70% receptor occupancy and 7 ng/mL mean plasma concentration.
Rapport Therapeutics (NASDAQ: RAPP) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its CNS drug development programs. The company's lead candidate RAP-219 showed promising results in PET and MAD-2 trials, demonstrating neuroanatomical specificity and favorable tolerability across 100 healthy subjects with no serious adverse events.
Key financial metrics include a Q4 2024 net loss of $20.0 million (vs $13.5 million in Q4 2023) and full-year net loss of $78.3 million. R&D expenses increased to $17.2 million in Q4 2024, while G&A expenses rose to $6.3 million. The company maintains a strong financial position with $305.3 million in cash and investments, expected to fund operations through 2026.
Notable upcoming milestones include:
- Phase 2a trial topline results in refractory focal epilepsy expected in Q3 2025
- Phase 2a trial initiation in bipolar mania planned for Q3 2025
- Ongoing development plans for diabetic peripheral neuropathic pain treatment
Rapport Therapeutics (Nasdaq: RAPP) has appointed Dr. Jeffrey Sevigny as Chief Medical Officer (CMO), effective immediately. Dr. Sevigny brings over 15 years of leadership experience in translational and clinical drug development, particularly in neuroscience and rare diseases.
Previously serving as CMO at Prevail Therapeutics (an Eli Lilly subsidiary) and SVP of Neuroscience at Eli Lilly, Dr. Sevigny has demonstrated success in building clinical development organizations and achieving corporate milestones including IPO and acquisition processes. His career includes leadership positions at major pharmaceutical companies including Roche, Biogen, Novartis, and Merck.
In his new role, Dr. Sevigny will oversee Rapport's clinical strategy and advance its pipeline of precision medicines, particularly the RAP-219 program, which has shown promising Phase 1 data. His expertise in late-stage clinical trials and regulatory approvals will be important for the company's development of treatments for central nervous system (CNS) disorders.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for CNS disorders, has announced its participation in two major investor conferences in March 2025.
The company will participate in:
- The TD Cowen 45th Annual Health Care Conference in Boston, featuring a fireside chat on March 4, 2025, from 3:10-3:40pm EST
- The Stifel 2025 Virtual CNS Forum, with a fireside chat scheduled for March 19, 2025, from 10:30-10:55am EST
Investors and interested parties can access live and archived webcasts of both presentations through the Investors section of Rapport's website at investors.rapportrx.com.
Rapport Therapeutics (NASDAQ: RAPP) announced new Phase 1 data for RAP-219, its CNS disorder treatment candidate. The PET trial demonstrated that RAP-219 achieved and exceeded target receptor occupancy within five days while maintaining good tolerability. The MAD-2 trial showed favorable results with faster titration and higher exposures than the initial MAD trial.
Key findings from four Phase 1 trials involving 100 healthy volunteers showed RAP-219 was generally well-tolerated with no serious adverse events, no TEAEs greater than Grade 2, and only three treatment discontinuations (3%). The PET trial confirmed TARPγ8-containing AMPA receptors are enriched in the hippocampus and cerebral cortex, with minimal presence in the cerebellum and brain stem.
The company announced that Bradley Galer stepped down as chief medical officer, with a search for successor underway. A Phase 2a proof-of-concept trial for focal epilepsy is ongoing with topline results expected in mid-2025.
Rapport Therapeutics (NASDAQ: RAPP) has announced positive Phase 1 data for RAP-219, its CNS disorder treatment candidate. The PET trial demonstrated that RAP-219 achieved and exceeded target receptor occupancy within five days of dosing, supporting the dosing regimen in the ongoing Phase 2a focal epilepsy trial.
Key findings from trials involving 100 healthy volunteers showed RAP-219 was generally well-tolerated with no serious adverse events, and only 3% treatment discontinuations. The drug demonstrated favorable tolerability across various dosing regimens, with no sedation or motoric impairments observed.
The PET trial confirmed TARP8-containing AMPA receptors are enriched in the hippocampus and cerebral cortex, with minimal presence in the cerebellum and brain stem. The MAD-2 trial showed successful dose escalation and faster therapeutic level achievement. The company expects topline data from the ongoing Phase 2a trial in focal epilepsy by mid-2025.
Rapport Therapeutics (NASDAQ: RAPP) presented data showing a significant correlation between reductions in RNS-measured long episodes (LEs) and clinical seizures in focal epilepsy patients. The analysis revealed that a 30% reduction in LEs corresponds to a ≥50% reduction in clinical seizures, validating their biomarker approach for ongoing trials.
The company presented additional findings at the American Epilepsy Society Annual Meeting, including Phase 1 results showing RAP-219 was well-tolerated at target therapeutic exposures, food interaction studies indicating flexible dosing options, and preclinical data demonstrating dose-dependent antiseizure effects. Rapport's Phase 2a proof-of-concept trial for RAP-219 is ongoing with topline data expected in mid-2025.
Rapport Therapeutics (NASDAQ: RAPP) announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (December 6-10, 2024, Los Angeles). The company will present new data on the correlation between long episode frequency reduction and clinically meaningful reduction in patient-reported seizures, derived from an RNS® System study.
The presentations include data from their Phase 2a trial of RAP-219, their lead product candidate for drug-resistant focal epilepsy. Four poster presentations will cover antiseizure effects, pharmacokinetics, safety, and tolerability studies. A Scientific Exhibit Room session will showcase these posters along with additional information about RAP-219's development and trial design.